Key to symbols
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
7.5. Drugs used in Chronic Kidney Disease
7.5.2. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Total Formulary
DAPAGLIFLOZIN (FORXIGA)
Restrictions:
Chronic Kidney Disease:
- Restricted to initiation by clinicians, either in primary or secondary care, experienced in the treatment of chronic kidney disease (CKD) for use in patients with an estimated glomerular filtration rate of ≥25 to ≤75 mL/min/1.73m2 at treatment initiation, who are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), and have a urine albumin-creatinine ratio of at least 23mg/mmol and/or type 2 diabetes mellitus.
For use in chronic heart failure, see section 2.5.6
EMPAGLIFLOZIN (JARDIANCE)
Restrictions:
Chronic Kidney Disease:
Restricted to initiation by clinicians, either in primary or secondary care, experienced in the treatment of chronic kidney disease (CKD) for use in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment:
- an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2 up to 45 mL/min/1.73m2, or
- an eGFR of 45 mL/min/1.73m2 up to 90 mL/min/1.73m2 and either:
- A urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more, or
- Type 2 Diabetes Mellitus (T2DM).
For use in chronic heart failure, see section 2.5.6